PCSK9 inhibitors in secondary prevention of MI

Gerd Hasenfuß

In which patients should proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors be used in the secondary prevention of myocardial infarction (MI)?

Gerd Hasenfuß, MD: These are the new drugs to lower cholesterols and they should be used in patients at high risk, in particular those with other sclerotic cardiovascular disease where the goal of the low-density lipoprotein (LDL) level of 70 mg/dL cannot be reached with statins and ezetimibe. In those patients the PCSK9 inhibitors should be used in addition. Another option would be to use them in patients who are not tolerant of statins.

See also

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.